Wegovy® is the first and only FDA-approved once-weekly GLP-1 RA medication to treat adults with MASH with liver scarring,* along with a reduced calorie diet and increased physical activity.
*Moderate to advanced liver scarring (fibrosis) without cirrhosis.
GLP-1 RA, glucagon-like peptide-1 receptor agonist; MASH, metabolic dysfunction–associated steatohepatitis.
Actor portrayal.
Results are from Week 72 of a medical study of adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis. 800 adults were included in the analysis. Health care professionals (HCPs) involved in the study were encouraged to optimize treatment for coexisting conditions and provide healthy lifestyle counseling for all participants.
In the study, significantly more adults taking Wegovy® achieved a reduction in MASH and no worsening of liver scarring† compared with those taking placebo (inactive injection). This means that more patients taking Wegovy® achieved:
†Defined as resolution of steatohepatitis (score of 0-1 for lobular inflammation, 0 for ballooning, and any value for steatosis) and no worsening of liver scarring.
In the study, significantly more adults taking Wegovy® achieved an improvement in liver scarring and no worsening of MASH‡ compared with those taking placebo. This means that more patients taking Wegovy® achieved:
‡Defined as at least one stage improvement in liver fibrosis and no worsening of steatohepatitis (defined as no increase from baseline in score for ballooning, lobular inflammation, or steatosis).
Actor portrayal.
Could Wegovy® help you take on MASH?
If you're living with MASH with liver scarring, you can take action with treatment. Wegovy® can treat MASH with liver scarring, along with the positive changes you are working to make through diet and physical activity.
800 adults with MASH with moderate to advanced liver scarring (fibrosis), but not cirrhosis, were included in the analysis at Week 72.
In the study, many adults with MASH had other related health conditions. About 73% had obesity, 56% had type 2 diabetes, 63% had high blood pressure, and 25% had dyslipidemia.
All adults in the study were randomly assigned to 2 groups. 534 were allocated to the group receiving Wegovy® (semaglutide) injection 2.4 mg once weekly, and 266 were allocated to the group receiving placebo once weekly. Health care professionals involved in the study were encouraged to optimize treatment for coexisting conditions and provide healthy lifestyle counseling for all patients.
To measure results during the study, a liver biopsy (small sample of liver tissue) at 72 weeks was compared to a biopsy taken before the person was treated in the study.
Talk to your doctor if you have questions and want to know more about the other Wegovy® indications.
Wegovy® is also indicated in combination with a reduced calorie diet and increased physical activity:
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This site is intended for US patients only.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.
Wegovy® may cause serious side effects, including:
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This site is intended for US patients only.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.